LOG IN
SIGN UP
MARKET
XENE
XENE
Xenon Pharmaceut
NASDAQ
36.47
+1.66
+4.77%
After Hours: 36.47 0 0.00% 16:01 11/28 EST
OPEN
35.30
PREV CLOSE
34.81
HIGH
36.51
LOW
35.30
VOLUME
384.18K
TURNOVER
0
52 WEEK HIGH
41.39
52 WEEK LOW
23.26
MARKET CAP
2.28B
P/E (TTM)
-19.9431
1D
5D
1M
3M
1Y
5Y
Where Xenon Pharmaceuticals Stands With Analysts
Benzinga · 10h ago
Wells Fargo Initiates Coverage On Xenon Pharmaceuticals with Overweight Rating, Announces Price Target of $50
Benzinga · 13h ago
--Guggenheim Adjusts Price Target on Xenon Pharmaceuticals to $49 From $53, Maintains Buy Rating
--Guggenheim Adjusts Price Target on Xenon Pharmaceuticals to $49 From $53, Maintains Buy Rating
MT Newswires · 11/11 09:21
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin,...
GlobeNewswire · 11/09 21:30
--Wedbush Lowers Xenon Pharmaceuticals' Price Target to $46 From $50, Keeps Outperform Rating
--Wedbush Lowers Xenon Pharmaceuticals' Price Target to $46 From $50, Keeps Outperform Rating
MT Newswires · 11/09 07:55
BRIEF-Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Reuters · 11/08 23:05
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 22:35
Xenon Pharmaceuticals Q3 EPS $(0.57) Misses $(0.52) Estimate, Sales $132.00K Miss $3.02M Estimate
Benzinga · 11/08 21:19
About XENE
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company is focused on advancing its ion channel neurology pipeline. The Company's products within its novel proprietary pipeline include clinical-stage candidates XEN496 and XEN1101, which are focused on treating neurological disorders, with a particular focus on epilepsy. XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). The XEN496 is a Kv7 potassium channel opener, is a pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy, or KCNQ2-DEE. The Company has promising partnered products within its pipelines, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.
Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.